Novavax to Host Conference Call to Discuss Fourth Quarter Financial Results and Operational Highlights on March 1, 2021
February 16 2021 - 8:00AM
Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing
next-generation vaccines for serious infectious diseases, today
announced it will report its fourth quarter 2020 financial results
and operational highlights following the close of U.S. financial
markets on Monday, March 1, 2021.
Conference call details are as follows: |
Date:Time:Dial-in number:Passcode:Webcast: |
March 1, 20214:30 p.m. U.S. Eastern Time (ET)(877) 212-6076
(Domestic) or (707) 287-9331
(International)3797013www.novavax.com/events |
|
|
Conference call and webcast replay: |
Date:Dial-in number:Passcode:Webcast: |
Starting at 7:30 p.m. ET, March 1, 2021(855) 859-2056 (Domestic) or
(404) 537-3406 (International)3797013www.novavax.com/events, until
June 1, 2021 |
About Novavax
Novavax, Inc. (Nasdaq: NVAX) is a biotechnology
company that promotes improved health globally through the
discovery, development and commercialization of innovative vaccines
to prevent serious infectious diseases. The company’s proprietary
recombinant technology platform combines the power and speed of
genetic engineering to efficiently produce highly immunogenic
nanoparticles designed to address urgent global health needs.
Novavax is conducting late-stage clinical trials for NVX-CoV2373,
its vaccine candidate against SARS-CoV-2, the virus that causes
COVID-19. NanoFlu™, its quadrivalent influenza nanoparticle
vaccine, met all primary objectives in its pivotal Phase 3 clinical
trial in older adults and will be advanced for regulatory
submission. Both vaccine candidates incorporate Novavax’
proprietary saponin-based Matrix-M™ adjuvant to enhance the immune
response and stimulate high levels of neutralizing antibodies.
For more information, visit www.novavax.com and
connect with us on Twitter and LinkedIn.
Contacts:
InvestorsNovavax,
Inc. Erika Schultz | 240-268-2022ir@novavax.com
Solebury TroutJennifer Porcelli |
617-974-8659jporcelli@soleburytrout.com
MediaAmy Speak | 617-420-2461Laura Keenan |
410-419-5755media@novavax.com
Novavax (NASDAQ:NVAX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Novavax (NASDAQ:NVAX)
Historical Stock Chart
From Apr 2023 to Apr 2024